Evidence map›Paper›PMID 26503213›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

The c.*229C > T gene polymorphism in 3'UTR region of the topoisomerase IIβ binding protein 1 gene and LOH in BRCA1/2 regions and their effect on the risk and progression of human laryngeal carcinoma.

Katarzyna Starska, Ewa Forma, Maria Nowacka-Zawisza, Iwona Lewy-Trenda, Piotr Ciesielski, Wioletta Pietruszewska, Michał Skóra, Magdalena Bryś

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Katarzyna StarskaI Department of Otolaryngology and Laryngological Oncology, Medical University of Łódź, Kopcinskiego 22, 90-153, Łódź, Poland. katarzyna.starska@umed.lodz.pl.
Ewa FormaDepartment of Cytobiochemistry, University of Łódź, Pomorska 142/143, 90-236, Łódź, Poland.
Maria Nowacka-ZawiszaDepartment of Cytobiochemistry, University of Łódź, Pomorska 142/143, 90-236, Łódź, Poland.
Iwona Lewy-TrendaDepartment of Pathology, Medical University of Łódź, Pomorska 251, 92-213, Łódź, Poland.
Piotr CiesielskiDepartment of Cytobiochemistry, University of Łódź, Pomorska 142/143, 90-236, Łódź, Poland.
Wioletta PietruszewskaI Department of Otolaryngology and Laryngological Oncology, Medical University of Łódź, Kopcinskiego 22, 90-153, Łódź, Poland.
Michał SkóraDepartment of Otolaryngology, Żeromski Specialist Hospital, os. Na Skarpie 66, 31-913, Kraków, Poland.
Magdalena BryśDepartment of Cytobiochemistry, University of Łódź, Pomorska 142/143, 90-236, Łódź, Poland.
University of Łódź · PLMedical University of Lodz · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Topoisomerase IIβ binding protein 1 (TopBP1), a multiple-BRCT-domain, protein plays crucial roles in chromosome replication, DNA damage repair, apoptosis, and cell cycle checkpoint signalling. The aim of this study was to identify five SNPs at loci potentially located in the 3'UTR region of the TopBP1 gene (rs185903567, rs116645643, rs115160714, rs116195487, rs112843513), their relationship with the risk of squamous cell laryngeal cancer (SCLC), tumor invasiveness, and prognosis. Genotyping was performed in 323 genetically unrelated individuals with SCLC and 418 randomly selected healthy volunteers. Allele-specific TopBP1 mRNA and protein expressions were determined by using real-time PCR and Western blotting techniques, respectively. LOH in BRCA1/BRCA2 was determined by using microsatellite markers. Compared to homozygous common allele carriers, heterozygosity for the T variant was associated with increased risk of SCLC (adjusted odds ratio [OR] = 9.83, 95 % confidence interval [CI]: 3.12-22.16, p dominant < 0.0001). The presence of risk allele at rs115160714 TopBP1 determined a higher incidence of nodal metastases (OR = 7.98, 95 % CI: 3.94-16.00, p = 0.001) and higher tumor grade (OR = 6.48, 95 % CI: 0.86-48.01, p = 0.03). The heterozygotes displayed diffuse tumor growth with no distinct borderline (OR = 3.10, 95 % Cl: 0.92-10.62, p = 0.049) and higher depth of invasion (OR = 2.66, 95 % Cl: 0.78-9.03, p = 0.04). Relationships were also identified between TopBP1 mRNA/protein expression and overall survival (p < 0.0001). The incidence of LOH in BRCA1/BRCA2 was significantly related to higher tumor grade and TFG (p < 0.05). The results of this study suggest that rs115160714 TopBP1 may be a genetic marker of etiology and progression in laryngeal cancer.

Indexed as

Genes, BRCA1Genes, BRCA23' Untranslated RegionsAgedCarcinoma, Squamous CellCarrier ProteinsCase-Control StudiesDisease ProgressionDNA-Binding ProteinsFemaleGene ExpressionGene FrequencyGenetic Association StudiesGenetic Predisposition to DiseaseHumansKaplan-Meier Estimate3' Untranslated RegionsCarrier ProteinsDNA-Binding ProteinsNuclear ProteinsTOPBP1 protein, humanBRCA1 and BRCA2 genesLaryngeal cancerLoss of heterozygosity (LOH)Single nucleotide polymorphism (SNP)TopBP1 gene/proteinTumor front grading (TFG)

Identifiers

PMID26503213
OpenAlexW1855634886

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.